|Bid||28.30 x 0|
|Ask||28.33 x 0|
|Day's Range||28.26 - 29.37|
|52 Week Range||23.60 - 36.52|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jim Cramer chats with Bausch Health CEO Joe Papa about the company's turnaround and how it's affected by drug pricing.
GE stock dropped 11% Thursday after the release of a negative report by forensic accountant Harry Markopolos. Wall Street is weighing in, and here’s what analysts and big investors are saying.
For his "Executive Decision" segment on Mad Money Wednesday night, Jim Cramer sat down with Joe Papa, chairman and CEO of Bausch Health Cos. , which just posted a three-cents-a-share earnings miss but with a 1% rise in revenues. Papa said he's very excited about Bausch's eye care segment, as Bausch & Lomb remains a strong brand with intense customer loyalty.
Today, Bausch Health reported its second-quarter earnings results before the market opened. It reported revenue of $2.15 billion in the quarter.
The healthcare company reported especially strong sales growth in the second quarter for gastrointestinal drug Xifaxan.
Bausch Health Companies (NYSE: BHC ) reported second-quarter sales of $2.15 billion, which met the analyst consensus estimate. This is a 1.03% increase over sales of $2.128 billion the same period last ...
Shares of Bausch Health Companies Inc. rallied 3.0% in premarket trading Tuesday, after the health care products company reported second-quarter revenue that rose in line with expectations and raised its full-year profit outlook. The net loss narrowed to $171 million, or 49 cents a share, from $873 million, or $2.49 a share, in the same period a year ago as operating results increased while interest expense and loss on extinguishment of debt declined. Excluding non-recurring items, adjusted net income rose to $372 million from $327 million, but the company did not provide adjusted per-share figures. Total revenue rose to $2.152 billion from $2.128 billion a year ago, in line with the FactSet consensus of $2.151 billion, as Bausch & Lomb/international sales miss expectations while Salix sales beat. For 2019, the company raised its revenue guidance range to $8.40 billion to $8.60 billion from $8.35 billion to $8.55 billion. The stock has run up 26.3% year to date through Monday, while the SPDR Health Care Select Sector ETF has gained 2.8% and the S&P 500 has advanced 13.5%.
Bausch Health Companies Inc. said Monday morning that it would be using cash flow from operations to pay down $100 million of its senior secured term loans this week. It will then have paid all mandatory amortization through the second quarter of 2020, the company said. Shares rose 1.9% in premarket trade, and the stock has gained 28.9% in the year to date through Friday. The S&P 500 has gained 20.7%.
It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.
Pershing Square Capital’s Bill Ackman has had a roller-coaster of success and failures in recent years. Perhaps no failure has been as highly publicized as his stake in Valeant Pharmaceuticals, which is now Bausch Health Companies Inc (NYSE: BHC). Ackman reportedly first took his massive stake in Valeant back in 2015 at an average price of around $196 per share.
gained on Tuesday after the health-sciences company said it had reduced its debt outstanding and introduced a new psoriasis-treatment lotion. The Laval, Quebec, company said it had paid down an additional $100 million of debt using cash from operations, eliminating any additional "mandatory amortization" for its fiscal 2020 first quarter. Calling the drug one of its "significant seven" -- a collection of products that could garner a predicted $1 billion in sales through 2024 -- Bausch Health expects Duobrii to be a strong revenue driver.
Bausch Health Companies Inc (NYSE: BHC ) jumped 3% on Tuesday after the company announced it has taken a major stride in paying down its massive debt load. Bausch, which changed its name from Valeant Pharmaceuticals ...
It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).
Bausch Health Companies Inc NYSE:BHCView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BHC totaled $1.20 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BHC credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In his second "Executive Decision" segment of his popular Mad Money program Thursday night, Jim Cramer sat down with Joe Papa, chairman and CEO of Bausch Health Cos. Papa started off by stating that it's the first anniversary of Lumify, BHC's newest treatment for red eyes, and already the product is among the most recommended by doctors and is selling at a $50 million annual run rate. Papa noted that BHC's strength comes from its diversification.
Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Salix segment performanceIn the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment—a rise of 5% YoY